Research progress on stereotactic radiation therapy for early non-small cell lung cancer
10.3760/cma.j.cn113030-20181023-00541
- VernacularTitle:立体定向放射治疗早期非小细胞肺癌的进展
- Author:
Hongfang YU
1
;
Zhilong YU
Author Information
1. 内蒙古医科大学附属医院放疗科，呼和浩特 010030
- From:
Chinese Journal of Radiation Oncology
2020;29(6):482-485
- CountryChina
- Language:Chinese
-
Abstract:
Stereotactic body radiation therapy (SBRT) refers to the use of stereotactic isocentric rotation technology, which concent rates high-energy radiation in the target area for a large dose of irradiation, causing irreversible biological damage, while the normal tissue is not or less exposed. Currently, SBRT is the standard treatment for inoperable patients with early non-small cell lung cancer (NSCLC). The efficacy of SBRT in the treatment of peripheral and central lung cancer has been validated, whereas there is no consensus on the dose and fractionation, which remains to be further explored. The clinical efficacy of SBRT combined with immunotherapy needs to be further studied. Therefore, the optimal dose and fractionation of SBRT for early peripheral and central NSCLC were discussed, the difference in the clinical efficacy among SBRT, lobectomy and thoracoscopic surgery was analyzed and the clinical efficacy of SBRT combined with immunotherapy was assessed, aiming to provide theoretical basis for the application of SBRT in clinical practice.
